Overexpression of EphA2 correlates with epithelial-mesenchymal transition-related proteins in gastric cancer and their prognostic importance for postoperative patients

Medical Oncology

Volumn 29, Issue 4, 2012, Pages 2691-2700

  Hou, Futao ^a   Yuan, Weijie ^a   Huang, Jin ^a   Qian, Liyuan ^b   Chen, Zhikang ^a   Ge, Jie ^a   Wu, Shaobin ^a   Chen, Jinxiang ^a   Wang, Jixu ^a   Chen, Zihua ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

EphA2; Epithelial mesenchymal transition; Gastric cancer; Immunohistochemistry; Prognosis

Indexed keywords

BETA CATENIN; EPHRIN RECEPTOR A2; UVOMORULIN; VIMENTIN;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; TUMOR DIFFERENTIATION;

ADULT; AGED; BETA CATENIN; CADHERINS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, EPHA2; STOMACH NEOPLASMS; VIMENTIN;

EID: 84868002881     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-0127-2     Document Type: Article

References (49)

1. Hohenberger P, Gretschel S. Gastric cancer. Lancet. 2003;362:305-15.
2. Dicken BJ, Bigam DL, Cass C, et al. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg. 2005;241:27-39.
3. Hess AR, Seftor EA, Gardner LM, et al. Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2). Cancer Res. 2001;61:3250-5.
4. Ireton RC. Chen J: EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics. Curr Cancer Drug Targets. 2005;5:149-57.
5. Lu C, Shahzad MM, Wang H, et al. EphA2 overexpression promotes ovarian cancer growth. Cancer Biol Ther. 2008;7:1098-103.
6. Yuan W, Chen Z, Wu S, et al. Expression of EphA2 and E-cadherin in gastric cancer: correlated with tumor progression and lymphogenous metastasis. Pathol Oncol Res. 2009;15:473-8.
7. Thiery JP, Acloque H, Huang RY, et al. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139:871-90.
8. Micalizzi DS, Farabaugh SM, Ford HL. Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia. 2010;15:117-34.
9. Tomita K, van Bokhoven A, van Leenders GJ, et al. Cadherin switching in human prostate cancer progression. Cancer Res. 2000;60:3650-4.
10. Schmalhofer O, Brabletz S, Brabletz T. E-cadherin beta-catenin and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev. 2009;28:151-66.
11. Benjamin JM, Kwiatkowski AV, Yang C, et al. AlphaE-catenin regulates actin dynamics independently of cadherin-mediated cell-cell adhesion. J Cell Biol. 2010;189:339-52.
12. Micalizzi DS, Farabaugh SM, Ford HL. Epithelial-Mesenchymal Transition in Cancer: Parallels Between Normal Development and Tumor Progression. J Mammary Gland Biol Neoplasia. 2010;15:117-34.
13. Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol. 2005;17:548-58.
14. Thaker PH, Deavers M, Celestino J, et al. EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res. 2004;10:5145-50.
15. Lin YG, Han LY, Kamat AA, et al. EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer. 2007;109:332-40.
16. Jawhari A, Jordan S, Poole S, et al. Abnormal immunoreactivity of the E-cadherin-catenin complex in gastric carcinoma: relationship with patient survival. Gastroenterology. 1997;112:46-54.
17. Zhou Y, Ran J, Tang C. Effect of celecoxib on E-cadherin, VEGF. Microvessel density and apoptosis in gastric cancer. Cancer Biol Ther. 2007;6:269-75.
18. Prudkin L, Liu DD, Ozburn NC, et al. Epithelial-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung. Mod Pathol. 2009;22:668-78.
19. Yang P, Yuan W, He J, et al. Overexpression of EphA2, MMP-9 and MVD-CD34 in hepatocellular carcinoma: implications for tumor progression and prognosis. Heptol Res. 2009;39:1169-77.
20. Cui XD, Lee MJ, Yu GR, et al. EFNA1 ligand and its receptor EphA2: potential biomarkers for hepatocellular carcinoma. Int J Cancer. 2010;126:940-9.
21. Brannan JM, Dong W, Prudkin L, et al. Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer. Clin Cancer Res. 2009;15:4423-30.
22. Wang LF, Fokas E, Bieker M, et al. Increased expression of EphA2 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients. Oncol Rep. 2008;19:151-6.
23. Kamat AA, Coffey D, Merritt WM, et al. EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer. Cancer. 2009;115:2684-92.
24. Merrit WM, Thaker PH, Landen CN Jr, et al. Analysis of EphA2 expression and mutant p53 in ovarian carcinoma. Cancer Biol Ther. 2006;5:1357-60.
25. Kataoka H, Igarashi H, Kanamori M, et al. Correlation of EPHA2 overexpression with high microvessel count in human primary colorectal cancer. Cancer Sci. 2004;95:136-41.
26. Guarino M, Rubino B, Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology. 2007;39:305-18.
27. Thiery JP. Epithelial-mesenchymal transition in tumor progression. Nat Rev Cancer. 2002;2:442-54.
28. Nieto MA. Epithelial-mesenchymal transitions in development and disease: old views and new perspectives. Int J Dev Biol. 2009;53:1541-7.
29. Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009;28:15-33.
30. Almeida PR, Ferreira VA, Santos CC, et al. E-cadherin immunoexpression patterns in the characterisation of gastric carcinoma histotypes. J Clin Pathol. 2010;63:635-9.
31. Zhou Y, Li G, Wu J, et al. Clinicopathological significance of E-cadherin, VEGF, and MMPs in gastric cancer. Tumour Biol. 2010;31:549-58.
32. Guarino M, Rubino B, Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology. 2007;39:305-18.
33. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009;17:9-26.
34. Liu C, Li Y, Semenov M, et al. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell. 2002;108:837-47.
35. Song S, Mazurek N, Liu C, et al. Galectin-3 mediates nuclear beta-catenin accumulation and Wnt signaling in human colon cancer cells by regulation of glycogen synthase kinase-3beta activity. Cancer Res. 2009;69:1343-9.
36. Fukuyama R, Niculaita R, Ng KP, et al. Mutated in colorectal cancer, a putative tumor suppressor for serrated colorectal cancer, selectively represses beta-catenin-dependent transcription. Oncogene. 2008;27:6044-55.
37. Lovatt M, Bijlmakers MJ. Stabilisation of β-catenin downstream of T cell receptor signaling. PLoS One. 2010;5:e12794.
38. Wang Q, Sun ZX, Allgayer H, et al. Downregulation of E-cadherin is an essential event in activating beta-catenin/Tcf-dependent transcription and expression of its target genes in Pdcd4 knockdown cells. Oncogene. 2010;29:128-38.
39. Miyazawa K, Iwaya K, Kroda M, et al. Nuclear accumulation of beta-catenin in intestinal-type gastric carcinoma: correlation with early tumor invasion. Virchows Arch. 2000;437:508-13.
40. Zhou YN, Xu CP, Han B, et al. Expression of E-cadherin and beta-catenin in gastric carcinoma and its correlation with the clinicopathological features and patient survival. World J Gastroenterol. 2002;8:987-93.
41. Wong SC, Lo ES, Lee KC, et al. Prognostic and diagnostic significance of beta-catenin nuclear immunostaining in colorectal cancer. Clin Cancer Res. 2004;10:1401-8.
42. Hsu HP, Shan YS, Jin YT, et al. Loss of E-cadherin and beta-catenin is correlated with poor prognosis of ampullary neoplasms. J Surg Oncol. 2010;101:356-62.
43. Kim MA, Lee HS, Lee HE, et al. Prognostic importance of epithelial-mesenchymal transition-related protein expression in gastric carcinoma. Histopathology. 2009;54:442-51.
44. Fuyuhiro Y, Yashiro M, Noda S, et al. Clinical significance of vimentin-positive gastric cancer cells. Anticancer Res. 2010;30:5239-43.
45. Polette M, Gilles C, de Bentzmann S, et al. Association of fibroblastoid features with the invasive phenotype in human bronchial cancer cell lines. Clin Exp Metastasis. 1998;16:105-12.
46. Gilles C, Polette M, Mestdagt M, et al. Transactivation of vimentin by beta-catenin in human breast cancer cells. Cancer Res. 2003;63:2658-64.
47. Fang WB, Ireton RC, Zhuang G, et al. Overexpression of EPHA2 receptor destabilizes adherens junctions via a RhoA-dependent mechanism. J Cell Sci. 2008;121:358-68.
48. Hess AR, Seftor EA, Gruman LM, et al. VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: implications for vasculogenic mimicry. Cancer Biol Ther. 2006;5:228-33.
49. Yuan WJ, Ge J, Chen ZK, et al. Over-expression of EphA2 and EphrinA-1 in human gastric adenocarcinoma and its prognostic value for postoperative patients. Dig Dis Sci. 2009;54:2410-7.